Epigenetic Therapeutic Targets in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 24 July 2025 | Viewed by 243
Special Issue Editor
2. Division of Biology, STEM, MBC College, Wellesley, MA 02482, USA
3. Division of Biology, STEM, RC College Boston, Boston, MA 02120, USA
Interests: research on epigenetic switch; epigenetics/genetics related to gene silencing; imprinting; embryogenesis and development; cancer progenitor cell formation; cancer progression and metastasis; signaling regulating epigenetics events; combination therapy of cancers by HDAC inhibitors; other epigenetic drugs and other drugs; integrin signaling related to thrombosis and cancer; inhibition of apoptosis and motility in cancer cells; inhibition of Syk tyrosine kinase and protease calpain related to platelet clot lysis and development of novel anti-thrombotic agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer involves the unregulated growth of cells, which can metastasize. The uncontrolled drive of the cell cycle is associated with genetic alterations, including mutations, chromosomal abnormalities, genomic instability, differential gene expression, and dysregulation of cellular signaling. There are six well-defined events associated with cancer, known as the hallmarks of cancer: resisting cell death, sustaining proliferative signaling, evading growth suppressors, activating invasion and metastasis, enabling replicative immortality, and inducing angiogenesis. Recent research suggests a role of epigenetic alterations in these processes, as well as in the formation of cancer progenitor cells and cancer stem cell formation. In contrast to mutations, epigenetic alterations are mainly reversible and thus can be manipulated. Most cancers relapse because standard therapies do not kill cancer progenitor cells and can produce drug resistance. Molecules designed to inhibit mutations often result in resistance. Epigenetic drugs are expected to reduce cancer relapse as a component of combination therapy, as they have the potential to kill cancer progenitor cells and sensitize drug-resistant cancer cells. Combination therapy, including epigenetic drugs, is possibly useful. Epigenetic alterations include histone modification and DNA methylation, as well as RNA methylation. In addition, different types of RNA, including micro-RNA and long non-coding RNAs, play a significant role in transcription. Aberrations in these processes possibly contribute to carcinogenesis. The current Special Issue entitled "Epigenetic Therapeutic Targets in Cancer" is designed to include articles addressing these issues, including both basic and clinical studies, reviews, and commentaries. It is an emerging area and lacks comprehensive coverage.
Dr. Sibaji Sarkar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- targets
- cancer
- tumor
- signaling regulation
- inhibitors
- drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
